Author

Y. Jamin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:mouse· 3 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Organism:human· 1

Frequent Co-Authors

E. Poon· 3 shared L. Chesler· 3 shared B. Martins da Costa· 2 shared A. Bellini· 1 shared A. Benito· 1 shared A. Carcaboso· 1 shared A. Goodman· 1 shared A. Montoya· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

E. Poon

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELS.

E. Tucker, I. Jimenez, L. Chen, A. Bellini, C. Gorrini, E. Calton, Q. Gao, H. Che, E. Poon, Y. Jamin, B. Martins da Costa, K. Barker, S. Shrestha, C. Hutchinson, S. Dhariwal, , G. Schleiermacher

This study evaluates lorlatinib, an ALK inhibitor, in combination with chemotherapy or idasanutlin in preclinical neuroblastoma models, finding synergy in models with high ALK expression.

Clinical Cancer Research · Apr 3, 2023Peer-reviewedCancer Biology

Indisulam targets RNA splicing and metabolism to serve as a novel therapeutic strategy for high-risk neuroblastoma

A. Nijhuis, A. Sikka, O. Yogev, L. Herendi, C. Eckold, G. Valbuena, Y. Liu, E. Kouloura, E. Poon, B. Martins da Costa, A. Benito, H. Kramer, A. Montoya, D. Carling, E. J. Want, , H. C. Keun

This study shows that indisulam, a sulphonamide, targets RNA splicing and metabolism to inhibit neuroblastoma growth and achieve complete tumor remission in preclinical models.

bioRxiv · Dec 18, 2020Cancer Biology

Sulfopin, a selective covalent inhibitor of Pin1, blocks Myc-driven tumor initiation and growth in vivo

C. Dubiella, B. J. Pinch, D. Zaidman, T. D. Manz, E. Poon, S. He, E. Resnick, E. M. Langer, C. J. Daniel, H.-S. Seo, Y. Chen, S. B. Ficarro, Y. Jamin, X. Lian, S. Kibe, , N. London

Sulfopin, a selective Pin1 inhibitor, reduces tumor initiation and growth in neuroblastoma models by targeting c-Myc pathways.

bioRxiv · Mar 20, 2020 · PreprintCancer Biology